Novo Nordisk is a pharmaceutical manufacturing company that specializes in Insulin, obesity, rare diseases, and diabetes.
Novo Nordisk is a pharmaceutical manufacturing company that specializes in Insulin, obesity, rare diseases, and diabetes. Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 5, 2018 | Post-IPO Equity | $22M | — | — | — | Detail |
May 8, 1981 | IPO | — | — | — | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Sep 29, 2022
Ventus Therapeutics
|
Corporate Round | $70M | Biotechnology | Yes |
Feb 17, 2022
Beta Bionics
|
Series C | $57M | Biotechnology | — |
Mar 16, 2021
Glooko
|
Series D | $30M | Diabetes | — |
Sep 24, 2020
Sundew
|
Seed | €1.51M | Agriculture | — |
Jan 5, 2016
IO Biotech
|
Series A | €11M | Biotechnology | — |
Novo Nordisk has had 4 exits. Novo Nordisk most notable exits include IO Biotech , Innate Pharma
Date | Company Name | Exit Type | Industry | |
---|---|---|---|---|
Nov 5, 2021 | IO Biotech | IPO | Biotechnology | Detail |
Oct 17, 2019 | Innate Pharma | IPO | Biopharma | Detail |
Sep 12, 2014 | Affimed | IPO | Biotechnology | Detail |
Dec 3, 2013 | Xencor | IPO | Biotechnology | Detail |
Novo Nordisk has acquired 10 organizations. Their most recent acquisition was ZymoGenetics on Jan 1, 1988. They acquired ZymoGenetics for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Jan 1, 1988
ZymoGenetics
|
Therapeutics | acquisition | — | Detail |
Oct 1, 2003
Aldaph SpA
|
Manufacturing | acquisition | — | Detail |
May 21, 2013
Xellia Pharmaceuticals
|
Biotechnology | — | $ 700M | Detail |
Aug 27, 2015
Calibrium
|
Biotechnology | acquisition | — | Detail |
Aug 27, 2015
MB2
|
Health Care | acquisition | — | Detail |